☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Immuno-Oncology
Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M
April 27, 2021
BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration
April 8, 2021
Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star
April 5, 2021
Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology
February 16, 2021
Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star
July 17, 2020
GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology
December 31, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.